Benedikt Timmerman

Benedikt is Venture Partner at IRDI SORIDEC Gestion where he advices on investments and serves on the boards of portfolio companies such as Ixaltis, Antabio and Aelis Farma. Benedikt was formerly CEO of Genticel and has over 25 years of experience in Life Science industry. He was the founder of BT Pharma in 2001, which became Genticel in 2010 and rose over 34 M € in venture funding. In 2014 he took the company public on Euronext in Paris and Brussels and hereby raised another 34.7 M €. In 2017 he merged Genticel into Genkyotex (GKTX). Previously, Benedikt held senior R & D and corporate licensing positions at NOVARTIS (1996 – 2000) and SANDOZ (1991 – 1996).

Benedikt holds an MSc in Biology and a PhD degree in Genetics from the University of Ghent, Belgium and an MBA from INSEAD, Fontainebleau, France.